東北大学

東北大学大学院医学系研究科
腎臓内科学分野
東北大学病院　腎臓・高血圧内科

論文・著書

～歴史ある論文・著書～

2011年

論文【英文】

  1. Morimoto R, Kudo M, Murakami O, Takase K, Ishidoya S, Nakamura Y, Ishibashi T, Takahashi S, Arai Y, Suzuki T, Sasano H, Ito S, Satoh F: Difficult-to-control hypertension due to bilateral aldosterone-producing adrenocortical microadenomas associated with a cortisol-producing adrenal macroadenoma. J Hum Hypertens 25, 114-121, 2011
  2. Uruno A, Matsuda K, Noguchi N, Yoshikawa T, Kudo M, Satoh F, Rainey WE, Hui XG, Akahira JI, Nakamura Y, Sasano H, Okamoto H, Ito S, Sugawara A: Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production. J Mol Endcrinol 46; 37-49, 2011
  3. Terawaki H, Nakao M, Nakayama K, Nakayama M, Kimura A, Takane K, Mitome J, Hamaguchi A, Ogura M, Yokoyama K, Ito S, Hosoya T. Peritoneal clearance and transport of methylglyoxal. Nephrol Dial Transplant　26(2); 753-764, 2011
  4. Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, Ito S. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 223(2):133-135, 2011
  5. Kuriyama C, Mori K, Nakagawa Y, Hoshikawa S, Ozaki H, Ito S, Inoue M, Ohta M, Yoshida K: Erythrocyte zinc concentration as an indicator to distinguish painless thyroiditis-associated transient hypothyroidism from permanent hypothyroidism. Endocr J 58(1):59-63, 2011
  6. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364: 907-917, 2011
  7. Ogawa S, Nako K, Okamura M, Senda M, Mori T, Ito S.　 Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy.　 Hypertens Res 34(3); 400-401, 2011
  8. Satoh F, Morimoto R, Iwakura Y, Ono Y, Kudo M, Takase K, Ito S: Primary aldosteronism : A Japanese perspective. Rev Endocr Metab Disord 12; 11-14, 2011
  9. Ota K, Dohi Y, Brydun A, Nakanome A, Ito S, Igarashi K. Identification of Senescence-Associated Genes and their Networks under Oxidative Stress by the Analysis of Bach1. Antioxid Redox Signal 14; 2441-2451, 2011
  10. Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T; for the Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group: Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 29(8):1649-1659, 2011
  11. Ishidoya S, Kaiho Y, Ito A, Morimoto R, Satoh F, Ito S, Ishibashi T, Nakamura Y, Sasano H, Arai Y: Single-center Outcome of Laparoscopic Unilateral Adrenalectomy for Patients With Primary Aldosteronism: Lateralizing Disease Using Results of Adrenal Venous Sampling. Urology 78(1); 68-73, 2011
  12. Zhu WJ, Nakayama M, Mori T, Nakayama K, Katoh J, Murata Y, Sato T, Kabayama S, Ito S: Intake of water with high levels of dissolved hydrogen (H2) suppresses ischemia-induced cardio-renal injury in Dahl salt-sensitive rats. Nephrol Dial Transplant 26; 2112-2118, 2011
  13. Suzuki T, Toyohara T, Akiyama Y, Takeuchi Y, Mishima E, Suzuki C, Ito S, Soga T, Abe T: Transcriptional regulation of organic anion transporting polypeptide SLCO4C1 as a new therapeutic modality to prevent chronic kidney disease. J Pharm Sci 100(9):3696-707, 2011
  14. Sugawara A, Uruno A, Kudo M, Matsuda K, Yang CW, Ito S: PPARγ agonist beyond glucose lowering effect. Korean J Intern Med 26(1):19-24, 2011
  15. Souma T, Abe M, Moriguchi T, Takai J, Yanagisawa-Miyazawa N, Shibata E, Akiyama Y, Toyohara T, Suzuki T, Tanemoto M, Abe T, Sato H, Yamamoto M, Ito S. Luminal alkalinization attenuates proteinuria-induced oxidative damage in proximal tubular cells.　 J Am Soc Nephrol. Apr;22(4):635-48. 2011
  16. Morohoshi K, Yoshida K, Nakagawa Y, Hoshikawa S, Ozaki H, Takahashi Y, Ito S, Mori K. Effects of synthetic retinoid Am80 on iodide-induced autoimmune thyroiditis in nonobese diabetic mice; Cell Immunol. 270; 1-4, 2011
  17. Morohoshi K, Osone M, Yoshida K, Nakagawa Y, Hoshikawa S, Ozaki H, Takahashi Y, Ito S, Mori K: The sphingosine 1-phosphate receptor modulator FTY720 prevents iodide-induced autoimmune thyroiditis in non-obese diabetic mice. Autoimmunity. 44; 490-495, 2011
  18. Nakamura Y, Satoh F, Morimoto R, Kudo M, Takase K, Gomez-Sanchez CE, Honma S, Okuyama M, Yamashita K, Rainey WE, Sasano H, Ito S: 18-Oxocortisol Measurement in Adrenal Vein Sampling as a Biomarker for Subclassifying Primary Aldosteronism. J Clin Endocrinol Metab. 96; E1272-E1278, 2011
  19. Toyohara T, Suzuki T, Akiyama Y, Yoshihara D, Takeuchi Y, Mishima E, Kikuchi K, Suzuki C, Tanemoto M, Ito S, Nagao S, Soga T, Abe T: Metabolomic profiling of the autosomal dominant polycystic kidney disease rat model. Clin Exp Nephrol. 15; 676-687, 2011
  20. Mori K, Yoshida K, Ishii K, Morohoshi K, Nakagawa Y, Hoshikawa S, Ozaki H, Takahashi Y, Ito S: Experimental autoimmune thyroiditis in human parvovirus B19 transgenic mice. Autoimmunity. 44(6); 483-489, 2011
  21. Uruno A, Noguchi N, Matsuda K, Nata K, Yoshikawa T, Chikamatsu Y, Kagechika H, Harigae H, Ito S, Okamoto H, Sugawara A. All-trans retinoic acid and a novel synthetic retinoid tamibarotene (Am80) differentially regulate CD38 expression in human leukemia HL-60 cells: possible involvement of protein kinase C-{delta}. J Leukoc Biol. 90; 235-247, 2011
  22. Nakayama M, Sato T, Miyazaki M, Matsushima M, Sato H, Taguma Y, Ito S: Increased risk of cardiovascular events and mortality among non-diabetic chronic kidney disease patients with hypertensive nephropathy: the Gonryo study. Hypertens Res. 34; 1106-1110, 2011
  23. Hashimoto J, Ito S: Central pulse pressure and aortic stiffness determine renal hemodynamics: pathophysiological implication for microalbuminuria in hypertension. Hypertension 58(5):839-846, 2011
  24. Ando K, Haneda M, Ito S, Kashihara N, Node K, Nangaku M, Shimosawa T, Kishimoto J, Fujita T. Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria. Cardiovasc Drugs Ther. 25(4):341-347, 2011
  25. Cao P, Ito O, Guo Q, Ito D, Muroya Y, Rong R, Mori T, Ito S, Kohzuki M: Endogenous hydrogen peroxide up-regulates the expression of nitric oxide synthase in the kidney of SHR. J Hypertens 29(6):1167-1174, 2011
  26. Koizumi K, Nakayama M, Zhu WJ, Ito S: Characteristic effects of methylglyoxal and its degraded product formate on viability of human histiocytes: a possible detoxification pathway of methylglyoxal. Biochem Biophys Res Commun 407(2):426-431, 2011
  27. Munakata M, Konno S, Ohshima M, Ikeda T, Miura Y, Ito S: High-normal blood pressure is associated with microalbuminuria in the general population: the Watari study. Hypertens Res 34(10):1135-1140, 2011
  28. Ogawa S, Kou Y, Nako K, Okamura M, Senda M, Mori T, Ito S: Diagnosis and Treatment of Diabetic Patients Requiring Insulin Who Repeatedly Manifest Hyperglycemia and Hypoglycemia Due to Anti-Insulin Antibodies (Case Study). Clinical Diabetes 29(4): 149-150, 2011
  29. Miyazato M, Ishidoya S, Satoh F, Morimoto R, Kaiho Y, Yamada S, Ito A, Nakagawa H, Ito S, Arai Y.　 Surgical outcomes of laparoscopic adrenalectomy for patients with Cushing's and subclinical Cushing's syndrome: a single center experience.　 Int Urol Nephrol 43; 975-981, 2011
  30. Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, Makino H; ORIENT study investigators. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study; Diabetologia. 54(12): 2978-2986, 2011
  31. Wang CH, Li F, Hiller S, Kim HS, Maeda N, Smithies O, Takahashi N. A modest decrease in endothelial NOS in mice comparable to that associated with human NOS3 variants exacerbates diabetic nephropathy. Proc Natl Acad Sci U S A.; 108(5):2070-2075, 2011
  32. Aoki S, Hoshi K, Kawakami J, Sato K, Satoh K, Mori K, Sugawara A, Saito Y, Yoshida K. Assisting the diagnosis of Graves' hyperthyroidism with pattern recognition methods and a set of three routine tests parameters, and their correlations with free T4 levels: Extension to male patients. Biomed Pharmacother; 65(2):95-104, 2011
  33. Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A; Task Force Committee on Primary Aldosteronism, The Japan Endocrine Society: Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. Endocr J 58(9):711-721, 2011
  34. Okamura M, Ogawa S, Ito S: Safety and Efficacy of Imidapril in the Treatment of Essential Hypertension; Therapeutics 3; 477-486, 2011
  35. Hashimoto J, Ito S: Response to Pulsatile Flow Analysis of the Femoral Artery; Hypertension 57; e12, 2011
  36. Kazuki Morohoshi, Yurie Takahashi, Kouki Mori. Viral Infection and Innate Pattern Recognition Receptors in Induction of Hashimoto's Thyroiditis. Discovery Medicine. 12(67):505-511, 2011.
  37. Nakagawa Y, Hoshikawa S, Ozaki H, Mori K. Acute thyroid swelling after fine-needle aspiration biopsy. International Journal of Case Reports and Images. 2(11):28-29, 2011.
  38. Kawasaki Y, Ishidoya S, Kaiho Y, Ito A, Satoh F, Morimoto R, Nakagawa H, Arai Y. Laparoscopic simultaneous bilateral adrenalectomy: assessment of feasibility and potential indications. Int J Urol 18(11):762-7, 2011
  39. Wang T, Satoh F, Morimoto R, Nakamura Y, Sasano H, Auchus RJ, Edwards MA, Rainey WE. Gene expression profiles in aldosterone-producing adenomas and adjacent adrenal glands. Eur J Endocrinol 164(4):613-9, 2011
  40. Takahashi K, Morimoto R, Hirose T, Satoh F, Totsune K. Adrenomedullin 2/intermedin in the hypothalamo-pituitary-adrenal axis. J Mol Neurosci 43(2):182-92, 2011

論文【邦文】

  1. 伊藤貞嘉：CKDと脳；BIO Clinica 26；78-83, 2011
  2. 伊藤貞嘉：電解質異常と疾患　高血圧と電解質異常；Mebio28(1)：61-69, 2011
  3. 伊藤貞嘉：利尿薬；治療薬UP-TO-DATE2011；メディカルレビュー社；215－217，2011
  4. 伊藤貞嘉：RENAAL RENAAL試験について教えてください；肥満と糖尿病10(1)；110-111, 2011
  5. 森建文、宮田敏男、佐藤博、伊藤貞嘉：AKI発症と酸化/カルボニルストレス；Modern Physician 31(1); 30-33, 2011
  6. 伊藤貞嘉：慢性腎臓病；臨床と研究88(2)；178-182，2011
  7. 伊藤貞嘉：虚血性腎症の血行動態；血圧18(3)；238-241, 2011
  8. 伊藤貞嘉：心腎連関；レジデント4(6)；50-59, 2011
  9. 三島英換、伊藤貞嘉：RAS阻害薬の適応と使いかた；Medical Practice28(6)；1073-1076, 2011
  10. 伊藤貞嘉：慢性腎臓病（CKD）と心血管イベント；PHYSICIANS THERAPY MANUAL4(4)；2011
  11. 阿部倫明：腎血管性高血圧；薬局62(4)；569-577, 2011
  12. 鳴海かほり、森建文、伊藤貞嘉：心腎連関；Cardiovascular Frontier 2(4): 268-272, 2011
  13. 伊藤貞嘉：Editorial；臨床透析27(9)：1147-1148, 2011
  14. 伊藤貞嘉：Trial & Meta-analysis　ROADMAP；臨床高血圧17(2)；140－141，2011
  15. 小川晋、伊藤貞嘉：高血圧の薬物療法；月刊糖尿病3(11)別冊糖尿病治療薬ハンドブック;180-188, 2011
  16. 伊藤貞嘉：腎障害と尿酸；血圧18(7)；622-626, 2011
  17. 伊藤貞嘉：糖尿病・慢性腎臓病・心筋梗塞既往患者の降圧目標は130/80mmHg未満か？；循環器内科70(4)；365-373, 2011
  18. 小泉賢治、伊藤貞嘉：腎疾患合併高血圧；日本臨床69(11)；2015-2019, 2011
  19. 伊藤貞嘉：ROADMAP試験；医学のあゆみ239(8)；857-858，2011
  20. 伊藤貞嘉：高血圧の管理目標；腎臓34(2)；144-155, 2011
  21. 阿部倫明、伊藤貞嘉：1．動脈硬化症腎動脈狭窄症と腎機能障害の患者におけるステント留置療法；Thrombosis and circulation19(3); 639-642, 2011
  22. 中道崇、森建文、伊藤貞嘉：脳・心・腎連関；臨床高血圧17(4)；230－237，2011
  23. 小川晋：血圧コントロール不良例に対する対策：次の一手は；月刊糖尿病3(7)；90－97，2011
  24. 橋本潤一郎：中心血圧；臨床透析27(9)；1244－1245，2011
  25. 岩倉芳倫、森本玲、工藤正孝、村上治、小野美澄、柳澤紀子、清元秀泰、高瀬圭、清治和将、高橋昭喜、石戸谷滋人、荒井陽一、中村保宏、鈴木貴、笹野公伸、伊藤貞嘉、佐藤文俊:初診時CKDを合併したPA症例の臨床上特徴及び治療予後に関する検討；日本内分泌学会雑誌　Vol. 87 Suppl.；56-58, 2011

著書【分担執筆】

  1. 伊藤貞嘉：高血圧性合併症の特徴と治療　３．腎疾患；日本高血圧学会専門医取得のための高血圧専門医ガイドブック改訂第2版；日本高血圧学会編；診断と治療社；136‐143，2011．2月
  2. 佐藤文俊、伊藤貞嘉：原発性アルドステロン症；病気と薬パーフェクトBOOK2011薬局増刊号；南山堂；666-671, 2011.3
  3. 伊藤貞嘉：高血圧と電解質異常；循環器医のための知っておくべき電解質異常；犀川哲典編集；MEDICAL VIEW；78－85，2011．5
  4. 伊藤貞嘉：マックル・ウェルズ症候群；症候群ハンドブック；井村裕夫総編集；中山書店；471, 2011．5
  5. 伊藤貞嘉：IDNT・IRMA2；高血圧ナビゲーター第3版；熊谷裕生、小室一成、堀内正嗣、森下竜一編集；メディカルレビュー社；204-205, 2011.6
  6. 伊藤貞嘉：2．慢性腎臓病を合併する高血圧治療においてレニン・アンジオテンシン系阻害薬をどのように使用すればよいのでしょうか？；EBM腎臓病の治療2011‐2012；富野康日己監修；中外医学社；158-161, 2011.6
  7. 小川晋、伊藤貞嘉：糖尿病慢性合併症（大血管症）；内分泌・糖尿病内科学；森昌朋編集；シュプリンガー・ジャパン；213-216, 2011.9
  8. 佐藤博：難治性ネフローゼ症候群（含む巣状分節性糸球体硬化症）に対する治療法にはどのようなものがあるのでしょうか？；EBM腎臓病の治療；富野康日己監修；中外医学社；77-82, 2011．6月
  9. 佐藤文俊、伊藤貞嘉：先端巨大症、中枢性尿崩症、Cushing症候群、原発性アルド ステロン症、Addison病、褐色細胞腫；画像提供；イヤーノートアトラス第4版；医療 情報科学研究所編集；㈱メディックメディア；D6,7,8,20-22,24, 2011.4
  10. 竹内和久、伊藤貞嘉：Bartter症候群；画像提供；イヤーノートアトラス第4版；医療情報科学研究所編集；㈱メディックメディア；F17, 2011.4
TOP